Neonatal morbidities and developmental delay in moderately preterm-born children

Jorien M Kerstjens1, Inger F Bocca-Tjeertes, Andrea F de Winter

  • 1Division of Neonatology, Beatrix Children's Hospital, University Medical Center, University of Groningen, Groningen, Netherlands. j.m.kerstjens@umcg.nl

Pediatrics
|July 11, 2012
PubMed

Insights

Hypoglycemia in moderately preterm infants significantly increases the risk of developmental delays. Preventing low blood sugar in these children may improve their preschool development outcomes.

Area of Science:

  • Neonatalogy
  • Developmental Pediatrics
  • Public Health

Background:

  • Moderately preterm infants (32-35 weeks' gestation) face higher risks of neonatal issues and developmental delays.
  • The specific impact of neonatal morbidities on later developmental outcomes remains unclear.

Purpose of the Study:

  • To investigate the effect of neonatal morbidities in moderately preterm children on their development at preschool age.
  • To identify specific neonatal conditions that contribute to developmental delays in this vulnerable population.

Main Methods:

  • A community-based cohort of 832 moderately preterm children (born 2002-2003) was studied.
  • Developmental outcomes were assessed at 43-49 months using the Ages and Stage Questionnaire.
  • Neonatal data, including Apgar scores, asphyxia, NICU admissions, and metabolic conditions like hypoglycemia and hyperbilirubinemia, were extracted from medical records.

Main Results:

  • Hypoglycemia (low blood sugar) and asphyxia were significantly associated with developmental delay.
  • Tertiary NICU admission and hyperbilirubinemia showed borderline nonsignificant associations.
  • In multivariate analysis, only hypoglycemia remained a significant predictor of developmental delay (OR: 2.19).

Conclusions:

  • Hypoglycemia is the primary neonatal morbidity linked to increased risk of developmental delay in moderately preterm children.
  • Preventive strategies targeting hypoglycemia could potentially improve developmental trajectories for these infants.
Abstract

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Development of the Oral Microbiota01:28

Development of the Oral Microbiota

The establishment of the oral microbiome begins before birth, challenging the long-held belief that the fetal oral cavity is sterile. The presence of oral microbes such as Streptococcus and Fusobacterium in amniotic fluid suggests that microbial exposure may occur in utero, potentially through translocation from the maternal oral or gastrointestinal tract. This early colonization primes the neonatal immune system and sets the stage for subsequent microbial succession. Maternal health,...
Neurulation01:30

Neurulation

Neurulation is the embryological process which forms the precursors of the central nervous system and occurs after gastrulation has established the three primary cell layers of the embryo: ectoderm, mesoderm, and endoderm. In humans, the majority of this system is formed via primary neurulation, in which the central portion of the ectoderm—originally appearing as a flat sheet of cells—folds upwards and inwards, sealing off to form a hollow neural tube. As development proceeds, the anterior...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...